Background
Study question
Methods
Protocol and registration
Study eligibility criteria
Preclinical model eligibility criteria
Oleic acid | |
Lipopolysaccharides | |
Acid aspiration | |
Hyperoxia | |
Saline lavage | |
Pulmonary ischemia/reperfusion | |
Nonpulmonary ischemia/reperfusion | |
Intravenous bacteria | |
Intrapulmonary bacteria | |
Peritonitis | |
Cecal ligation and puncture | |
Trauma/Shock | |
Mechanical ventilation (ventilator-induced lung injury) | |
Chemical or chemotherapeutic injury (such as detergents) | |
Pancreatitis | |
Burns |
Interventions
Class | Example of therapies |
---|---|
Interleukins | IL-10, IL-2 |
Cell therapy | MSCs, MSC-derived microvesicles |
Adrenergic beta-agonists | Salbutamol, albuterol, sultanol, proventil |
Growing factors | Fibroblast growing factors, keratinocyte growth factor, endothelial growth factor |
RAGE modulators | Anti-RAGE antibody, recombinant soluble RAGE, gene knockout, endogenous secretory RAGE |
Corticosteroids | Glucocorticoids, mineralocorticoids, 3-oxo steroid, 17-ketosteroids, domolene, cortifan, epicortisol, komed-hc, heb-cort, prednisone, encortone, panasol, deltacortisone, decortisyl, decortin, predeltin, orasone, prednidib, prednisone, dacortin, cortancyl, solupred, deltasone, pronisone, sterapred, encorton, panafcort, delta-dome, dehydrocortisone, prednisonum, lisacort, ultracorten, winpred, metacortandracin, meticorten, prednisolone, predate, prednisolone, di-adreson f, delta-1-hydrocortisone, prednisolonum, sterane, meti derm, metacortandralone, predonine |
Anticoagulant agents | Heparin, antithrombin, plasminogen activator, fibrinolytic agents, tissue factor pathway inhibitor, lipoprotein-associated coagulation inhibitor, thrombin-thrombomodulin complex, thrombin receptor, activated protein C, drotrecogin alfa activated |
Halogenated agents | Sevoflurane, desflurane, isoflurane |
Comparison
Preclinical primary endpoint
Features | Relevant measurements |
---|---|
Histological evidence of lung injury | Accumulation of neutrophils in the alveolar/interstitial space Formation of hyaline membranes Proteinaceous debris in alveolar space Proteinaceous debris in alveolar space Thickening of the alveolar wall Injury by a standardized histology score Evidence of hemorrhage Areas of atelectasis Gross macroscopic changes such as discoloration of the lungs |
Alteration of the alveolar capillary barrier | Increased extravascular lung water content Accumulation of protein/tracer in airspaces/extravascular space Total BAL protein concentration BAL concentration of high molecular weight proteins Vascular filtration coefficient Translocation of a protein from the airspaces into plasma Increased lung lymph flow, lymph protein concentration |
Inflammation | BAL total neutrophil counts Lung MPO activity Concentrations of cytokines and chemokines in lung tissue, in BAL fluid, and/or in plasma |
Physiological dysfunction | Hypoxemia Increased A-a oxygen difference |
Preclinical secondary endpoints
Information sources
Study selection
Data collection and process and data items
Categories | Main items |
---|---|
Study characteristics | DOI, Num ID (specific number ID for the purpose of the meta-analysis), title, author, year, country and journal of publication, country of study, mono/multicentric |
Study population (experimental model) | Animal species or ex vivo model, age, gender, strain, weight, and comorbidity |
Type of acute lung injury model | As defined in Table 1, with timing |
Intervention | Type (see Table 2), number, timing, mode of administration, dose |
Co-intervention | Resuscitation fluids, antibiotics, mechanical ventilation parameters, mode of anesthesia, drugs, etc. |
Preclinical endpoints | As defined in Table 3 |
Risk of bias assessments (Cochrane risk of bias tool) | Randomization, allocation, blinding and completeness of follow-up |
Quality of reporting of individual preclinical studies | ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines elements |
Assessment of risk of bias
Assessment of construct validity and external validity
Category | Items |
---|---|
Animal species and strain (for mice) | Human lung preparation, mouse, rat, sheep, pig, rabbit, dog or others |
Animal age | Young, middle-aged, and mature, depending on species |
Animal gender | Male, female, both |
Comorbidity | Yes or no, type |
Model of acute lung injury | As defined in Table 1 |
Severity of lung injury | Lung injury score |
Intervention type | The drug, mode of administration and dose |
Timing of intervention regarding to acute lung injury induction | Before lung injury, 0 to 1, 1 to 6, and > 6 h after lung injury |
Type of control | Injured, non-injured |
Use of co-interventions | Resuscitation fluids, use of antibiotics, type of anesthesia, mechanical ventilation strategy |
Number of study centers | Single versus multi-center |